Updates

U.S. spending on mental health and substance use treatment increased from $40.9 billion in 2000 to $139.6 billion in 2021, outpacing overall medical spending growth. The study finds that most of this increase was associated with growth in the number of treated cases —...

This first randomized, quadruple-blind clinical trial of psilocybin for cocaine use disorder found that a single psilocybin dose combined with manualized psychotherapy produced more cocaine‑abstinent days, higher rates of complete abstinence, and fewer lapses over 180...

A new SAMHSA advisory guides primary care providers, pediatricians, and geriatricians on identifying and treating cannabis use disorder across all life stages—from adolescence through pregnancy and older adulthood. The advisory notes that cannabis use disorder affects...

About 70,000 Americans died of drug overdoses in 2025, about 14% fewer than the previous year, according to preliminary government data. It was the third straight annual drop, making it the longest decline in decades, according to recently released federal data. The...

Low-risk drinking guidelines seldom incorporate quality of life (QoL). This secondary data analysis explores the relationship between drinking patterns and QoL. Study: Informing low-risk drinking guidelines: a secondary, cross-sectional data analysis of alcohol use...